Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of OSE-127 in moderate to severe active ulcerative colitis after prior treatment failure or intolerance
MOH_2023-02-14_012351Phase 2Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing OSE-127 induction then open-label OSE-127 with Placebo induction then open-label OSE-127 (2 arms). Primary endpoint: Reduction in modified Mayo score. Started Nov 2022; status: completed.
02
Drugs
lusvertikimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-02-14_012351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-14_012351.